The effect of hypoxia on the uptake, replication and lytic potential of group B adenovirus type 3 (Ad3) and type 11p (Ad11p)

Gene Therapy
B H ShenT W Hermiston

Abstract

Replicating, tumor selective viruses are being tested as potential treatments for human cancers. Hypoxia is a pathophysiological cancer condition that alters the lytic potential of the replication-competent adenovirus serotype 5 (Ad5) virus by a mechanism independent of receptor levels or internalization rates. We extend these initial studies to examine the potential effects of hypoxia on the group B adenoviruses (Ads), adenovirus type 3 (Ad3) (group B1) and adenovirus type 11p (Ad11p) (group B2). Receptor expression (CD46) is not altered by hypoxia. However, the lytic potential is compromised in a cell-dependent fashion. Consequently, our study suggests that group B replicating Ad-based treatments, like the group C Ad-5-based viruses, will need to be modified in order to effectively treat hypoxic components of human tumors.

References

Feb 23, 2000·Journal of Virology·D M ShayakhmetovA Lieber
Mar 29, 2001·Molecular Therapy : the Journal of the American Society of Gene Therapy·J G HeckerV R Irion
Jul 12, 2002·Current Gene Therapy·Q WuJ Xiang
Jul 5, 2003·Virology·P Seshidhar ReddySheila Connelly
Aug 14, 2003·Journal of Virology·Anna SegermanNiklas Arnberg
Nov 6, 2003·Molecular Therapy : the Journal of the American Society of Gene Therapy·Fuminori SakuraiTakao Hayakawa
Apr 14, 2004·Journal of Virology·Dominique SirenaSilvio Hemmi
Oct 29, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·Won-Kyung ChoDong-Soo Im
Dec 30, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Dawn E PostErwin G Van Meir
Feb 4, 2005·Gene Therapy·B H Shen, T W Hermiston

❮ Previous
Next ❯

Citations

May 26, 2009·Chemical Reviews·Christopher Alvarez-BreckenridgeE Antonio Chiocca
Apr 18, 2008·Gene Therapy·T-C Liu, D Kirn
Jun 21, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Caroline J BreitbachJohn C Bell
May 17, 2013·Future Virology·Sergei NekhaiSubhash Dhawan
Oct 10, 2008·The British Journal of Radiology·R L CowenK J Williams
Feb 6, 2010·Expert Opinion on Biological Therapy·Karoly TothWilliam S M Wold
Nov 4, 2008·Expert Opinion on Drug Delivery·Houria BachtarziKerry Fisher
Dec 29, 2015·Molecular Therapy : the Journal of the American Society of Gene Therapy·Alison TedcastleKerry D Fisher
Jul 25, 2009·Journal of Cellular Physiology·Sharroya CharlesSergei Nekhai
Mar 27, 2015·Human Gene Therapy·Philip G JakemanLeonard W Seymour
Apr 20, 2010·Cytokine & Growth Factor Reviews·Jeffrey Wojton, Balveen Kaur
Apr 14, 2017·Journal of Surgical Oncology·Ahmad Rahal, Benjamin Musher
Jun 15, 2010·Viruses·Han Hsi WongYaohe Wang
Dec 25, 2010·Cancer Gene Therapy·O HemminkiA Hemminki
Dec 19, 2016·American Journal of Clinical Dermatology·Praveen K BommareddyHoward L Kaufman
Jul 16, 2020·Communications Biology·Xiaodong ZhuangJane A McKeating
Aug 24, 2020·Current Problems in Cancer·Nasser Hashemi GoradelBabak Negahdari
Apr 9, 2021·JCI Insight·Richard HuangMichael Ohh

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.